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buffered saline (TBS), immunoprecipitates were eluted through incubation with FLAG peptide (0.15 mg/ml) in TBS, and further characterized (see below). In parallel, immunoprecipitation of cell extracts from HeLa cells expressing APE1 FLAG-tagged was also performed with a resin lacking the FLAG antibody.
Immunofluorescence confocal and Proximity Ligation analyses
Immunofluorescence procedures and Proximity Ligation Assay (PLA) were carried out as described earlier 3 . To study the interaction between APE1 and three identified protein interactors in vivo, we used the in situ Proximity Ligation Assay technology (Duolink, Sigma-Aldrich). After incubation with monoclonal anti-APE1 (NB 100-116, Novus) (1:100) for 3 h, at 37 °C, cells were incubated with polyclonal anti-SFPQ (ab38148, Abcam, Cambridge, MA) (1:200), anti-DHX9 (A300-854A, Bethyl Laboratories, USA) (1:100), anti-hnRNPK (ab70492, Abcam) (1:200) and anti-hnRNPA2B1 (PA5-34939, Thermo Fisher Scientific, USA) (1:500), overnight, at 4 °C. PLA was performed following the manufacturer's instructions. Technical controls, represented by HeLa cell clones silenced for APE1 expression, resulted in the complete loss of PLA signal. Cells were visualized through a Leica TCS SP8 confocal system (Leica Microsystems GmbH, Germany).
Antibodies used and Western blotting analysis
For Western blotting analyses, cell lysates were resolved on 12% T SDS-PAGE, transferred onto nitrocellulose membranes (Amersham TM Protran TM , GE Healthcare) and probed with antibodies for APE1 (NB 100-116, Novus) (1:1000), FLAG (F1804, SIGMA) (1:5000), LSD1 (ab129195, Abcam) (1:10000), β-tubulin (T0198, SIGMA) (1:2000) and NPM1 (ab15440, Abcam) (1:1000). The corresponding secondary antibodies labeled with IR-Dye (anti-rabbit IgG IRDye 680 and anti-mouse IgG IRDye 800) were used. Detection and quantification was performed with the Odyssey CLx Infrared imaging system (LI-COR GmbH, Germany). The membranes were scanned in two different channels using an Odyssey IR imager; protein bands were quantified using Odyssey software (Image Studio 5.0).
Proteomic analysis
Protein digests of gel slices from immunoprecipitated material of whole, nuclear and cytoplasmic cell extracts of HeLa cell clones expressing ectopic APE1 FLAG-tagged protein or stably transfected with the empty vector (SCR) were analyzed through Mass-Spectrometry. As a negative control, identical cell extracts from HeLa cells expressing APE1 FLAG-tagged were co-immunoprecipitated, in parallel, with a resin lacking the FLAG antibody (res). Mass-Spectrometry analyses were performed with a nanoLC-ESI-Q-Orbitrap-MS/MS platform consisting of an UltiMate 3000 HPLC RSLC nano system (Thermo Fisher Scientific, USA) coupled to a Q-ExactivePlus mass spectrometer through a Nanoflex ion source (Thermo Fisher Scientific). Peptides were loaded on an Acclaim PepMap TM RSLC C18 column (150 mm × 75 μm ID, 2 μm particles, 100 Å pore size) (Thermo Fisher Scientific) and eluted with a gradient of solvent B (19.92/80/0.08 v/v/v water/acetonitrile/formic acid) in solvent A (99.9/0.1 v/v water/formic acid), at a flow rate of 300 nl/min. The gradient of solvent B started at 3%, increased to 40% over 40 min, raised to 80% over 5 min, remained at 80% for 4 min, and finally returned to 3% in 1 min, with a column equilibrating step of 30 min before the subsequent chromatographic run. The mass spectrometer operated in data-dependent mode using a full scan (m/z range 375-1,500, a nominal resolution of 70,000, an automatic gain control target of 3,000,000, and a maximum ion target of 50 ms), followed by MS/MS scans of the 10 most abundant ions. MS/MS spectra were acquired in a scan m/z range 200-2000, using a normalized collision energy of 32%, an automatic gain control target of 100,000, a maximum ion target of 100 ms, and a resolution of 17,500. A dynamic exclusion value of 30s was also used. Duplicate analysis of each sample was performed to increase the number of identified peptides/protein coverage. variable modifications. Peptide mass tolerance and fragment mass tolerance were set to ± 10 ppm and ± 0.05 Da, respectively. Proteolytic enzyme and maximum number of missed cleavages were set to trypsin and 2, respectively. Protein candidates assigned on the basis of at least two sequenced peptides and Mascot score ≥30 were considered confidently identified. Definitive peptide assignment was always associated with manual spectra visualization and verification. Results were filtered to 1% false discovery rate. A comparison with results from the corresponding samples from control experiments (SCR and res) allowed to identify contaminant proteins in each experiment that, despite their abundance, were removed from the list of APE1-interacting partners ( Supplementary Table S1 and S2).
Cell viability and proliferation
Cell viability was measured by using the
assay (Celltiter 96 Aqueous One solution cell proliferation assay, Promega) on cells grown in 96-well plates and treated with Compound #3 4 and rotenone for 24 h. After treatment, the MTS solution was added to each well and the plates were incubated for 2 h, at 37 °C. Absorbance was measured at 490 nm by using a multi-well plate reader. The values were standardized to wells containing media alone.
Supplementary Figures
Supplementary Figure S1 .
A) Interaction experiments on the APE1-binding proteins identified in this study. The PLA technology was used to evaluate in vivo the APE1-SFPQ, -DHX9 and -hnRNPK interaction. The PLA reaction was performed following manufacturer's instructions. Different scan areas and zoomed cells are presented relative to HeLa cell clones.
B) The PLA reaction was carried out using anti-APE1 and anti-SFPQ antibodies in A549 cell lines silenced for APE1 (siAPE1) or in relative control cell lines transfected with a scramble siRNA (SCR).
C) The PLA reaction was carried out using anti-APE1 and anti-hnRNPA2B1 antibodies in JHH-6 cell lines silenced for APE1 (siAPE1) or in relative control cell lines transfected with a scramble siRNA (SCR).
Supplementary Figure S2.
Interaction experiments on the APE1-binding proteins identified in this study. The PLA technology was used to evaluate in vivo the APE1-SFPQ, -DHX9 and -hnRNPK interaction. The PLA reaction was performed following manufacturer's instructions. HeLa cells clones silenced for the expression of APE1
were seeded on a glass coverslip and the PLA reaction was carried out using anti-APE1 and anti-SFPQ represents the clones silenced for APE1. Actin was used as loading control.
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Supplementary Figure S3 .
Venn diagram showing the common elements between the APE1-PPIs (n=531), the genes that were differentially expressed upon siAPE1 (n=836) and the genes whose transcripts were bound by APE1 in the RIP-seq experiment (n=913). Globally, APE1 regulates 95 unique genes at the transcriptional or posttranscriptional level in HeLa cells.
Supplementary Figure S4.
A) Bad Prognosis network of the HNSC dataset formed by the interactors of APE1. Symbolism and coloring of APE1, nodes and upstream regulators is identical to that shown in Fig 6. B) Kaplan-Meier plot for the HNSC bad prognosis network.
C) Functional annotation of the HNSC bad prognosis network based on Gene Ontology -Biological
Process terms (p<0.05). In the pie chart, the percentage of the genes enriched in the pathways are given next to the enriched terms. 
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Asterisks represent a significant difference with respect to untreated cells. Data were evaluated statistically by two-tails Student t-test.
Supplementary Figure S13. A) Uncropped blots for Figure 2 . Figure S2C . Supplementary Table S1 . Supplementary Table S2 .
B) Uncropped blots for Supplementary
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Supplementary Tables
APE1-interacting
Identification details of the APE1-interacting proteins shown in Supplementary Table S1 . Reported are the identified proteins (blue cells) and peptides (pink cells), as well as the corresponding identification S12 parameters. We show the information on fraction (WCE, NCE or CCE), protein false discovery rate Supplementary Table S3 .
The literature evidences for the APE1-interacting partners described in this study. Supplementary Table S4 . C, F &I) are highlighted. For abbreviations, see Supplementary Table S6 . Supplementary Table S5 .
Identification of enriched transcription factor binding sites (TFBS) in the APE1 interactome gene promoters (-2500, -1nt from the TSS) using the LASAGNA-Search 2.0 tool. Worksheet "LASAGNA-Search-results_APE1_PPI" contains the raw results of the motif discovery analysis, showing for each promoter (n=531) the list of significantly enriched TFBS, sorted by increasing position within the FASTA formatted genomic sequence, as well as the matching sequence, strand, score, p-value and e-value. The worksheet "LASAGNA-APE1_PPI_Top10_pval" contains, for each promoter, the top10 most S13 informative hits, sorted by descending score and p-value (col. A-G). A list of unique transcription factors (TFs) binding these sites is shown in col. I, as well as a summary table indicating the overall number of promoters associated with every enriched TFBS, sorted by descending number of promoters (col. M-N). Supplementary Table S6 .
Abbreviations used for TCGA datasets. Supplementary Table S7 .
APE1-PPI bad prognostic signatures top regulators analysis. GeneXplain identification of the Top 3
putative master regulators of bad prognostic genes in the 11 selected TCGA cancer datasets (ranked by ascending Ranks sum). Bibliographic references are given for the association with the proliferation, apoptosis and resistance functional terms, indicating the involvement of top upstream regulators in these pathways (x indicates that no reference was found). Supplementary Table S8 .
GeneXplain identification of the Top10 putative master regulators of the APE1-PPI global network (ranked by ascending Ranks sum). 
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